Andrew Huberman, a well-known neurobiology professor and host of the Huberman Lab podcast, has joined the board of Hims & Hers. This move signifies his growing involvement in the consumer-health sector, which he has significantly influenced through his insights on sleep, fitness, hormones, supplements, and longevity. Huberman will also provide science and brand marketing advice and offer marketing support through his podcast.
Despite his new role, Huberman assures that his content will remain unbiased. He serves alongside notable board members like former Netflix CFO David Wells and former DoorDash CFO Kofi Amoo-Gottfried. Hims & Hers, primarily known for hair loss and erectile dysfunction treatments, is expanding into weight loss, testosterone, preventive care, and peptides.
Huberman emphasized the mutual goals he shares with Hims CEO Andrew Dudum, particularly in making personalized healthcare more accessible. Previously advising fitness and sleep brands, Huberman’s role here includes fiduciary duties, marking a unique partnership with direct involvement in company strategy.
Huberman and Dudum developed their partnership over several months, discussing their shared perspective on the future of consumer healthcare. Both highlight the need for accessible care, aiming to bridge the gap between traditional healthcare services and high-end care.
Hims caters to nearly 3 million customers, using its pharmacy and manufacturing capabilities to provide a range of treatments discussed by Huberman.
“Huberman’s influence extends the reach of Hims’ offerings, promising a significant impact on consumer healthcare,” a source noted.
Hims is also venturing into areas like testosterone and peptides, topics frequently addressed by Huberman. The company recently acquired a peptide facility, suggesting a strong commitment to advancing its offerings in this area.
Peptides such as BPC-157, once limited to niche biohacking, are becoming mainstream. Hims plans to launch Peptides+, offering wellness therapies like NAD+ and vitamin B12, subject to regulatory approval. Huberman reiterates his commitment to responsible advocacy of peptide use, emphasizing the importance of careful information dissemination.
The Huberman Lab YouTube channel, with over 8 million subscribers, will continue to deliver content on benefits, risks, and uncertainties in the field. Huberman reaffirms his commitment to educational integrity, with Hims supporting his independent content creation.
As Huberman’s media company, Scicomm Media, plans to run podcast ads for Hims & Hers, the challenge remains in maintaining the rigor of independent scientific guidance.
“Educating consumers to navigate wellness information critically is essential,” said Huberman, reflecting on the responsibility that comes with his dual role.
